Carbon nanotubes loaded with anticancer drugs: A platform for multimodal cancer treatment

Carbon Nanostructures

Volumn 0, Issue 9783642148019, 2011, Pages 223-245

  Heister, Elena ^a   Neves, Vera ^a   Silva, S Ravi P ^a   McFadden, Johnjoe ^a   Coley, Helen M ^a  

^a UNIVERSITY OF SURREY   (United Kingdom)

Author keywords

Anticancer drug; Carbon nanotubes; Drug delivery system; Folate receptor; Target drug delivery

Indexed keywords

CARBON NANOTUBES; CHEMOTHERAPY; CONTROLLED DRUG DELIVERY; CYTOLOGY; DISEASES; DRUG INTERACTIONS; MAMMALS; MEDICAL NANOTECHNOLOGY;

ANTI-CANCER CHEMOTHERAPY; ANTICANCER DRUG; DRUG DELIVERY SYSTEM; DRUG DELIVERY VEHICLES; FOLATE RECEPTOR; INNER CAVITIES; MAMMALIAN CELLS; THERAPEUTIC AGENTS;

TARGETED DRUG DELIVERY;

EID: 85006463907     PISSN: 21913005     EISSN: 21913013     Source Type: Book Series    
DOI: 10.1007/978-3-642-14802-6_12     Document Type: Chapter

References (62)

1. Jemal, A., Siegel, R., Ward, E., et al.: Cancer statistics 2009. CA Cancer J. Clin. 59, 225–249 (2009)
2. Kuper, H., Adami, H.O., Boffetta, P.: Tobacco use, cancer causation and public health impact. J. Intern. Med. 251(6), 455–466 (2002)
3. Bourdes, V., Boffetta, P., Pisani, P.: Environmental exposure to asbestos and risk of pleural mesothelioma: review and meta-analysis—Environmental exposure to asbestos and mesothelioma. Eur. J. Epidemiol. 16(5), 411–417 (2000)
4. Rigel, D.S.: Cutaneous ultraviolet exposure and its relationship to the development of skin cancer. J. Am. Acad. Dermatol. 58(2), S129–S132 (2008)
5. zur Hausen, H.: Viruses in human cancers. Science 254(5035), 1167–1173 (1991)
6. Frank, T.S.: Hereditary cancer syndromes. Arch. Pathol. Lab. Med. 125(1), 85–90 (2001)
7. Targeted Cancer Therapies. National Cancer Institute Fact Sheet 749 (2009)
8. Hait, W.N.: Targeted cancer therapeutics. Cancer Res. 69(4), 1263–1267 (2009)
9. McCarron, P.A., Olwill, S.A., Marouf, W.M.Y., et al.: Antibody conjugates and therapeutic strategies. Mol. Interv. 5(6), 368–380 (2005)
10. Byrne, J.D., Betancourt, T., Brannon-Peppas, L.: Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv. Drug Del. Rev. 60(15), 1615–1626 (2008)
11. Kirpotin, D.B., Drummond, D.C., Shao, Y., et al.: Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res. 66(13), 6732–6740 (2006)
12. Lee, L.S., Conover, C., Shi, C., et al.: Prolonged circulating lives of single-chain Fv proteins conjugated with polyethylene glycol: A comparison of conjugation chemistries and compounds. Bioconjug. Chem. 10(6), 973–981 (1999)
13. Farokhzad, O.C., Cheng, J.J., Teply, B.A., et al.: Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc. Natl. Acad. Sci. USA 103(16), 6315–6320 (2006)
14. Proske, D., Blank, M., Buhmann, R., et al.: Aptamers—basic research, drug development, and clinical applications. Appl. Microbiol. Biotechnol. 69(4), 367–374 (2005)
15. Rusconi, C.P., Roberts, J.D., Pitoc, G.A., et al.: Antidote-mediated control of an anticoagulant aptamer in vivo. Nat. Biotechnol. 22(11), 1423–1428 (2004)
16. 0 -O-methyl aptamer to VEGF. Chem. Biol. 12(1), 25–33 (2005)
17. Garanger, E., Boturyn, D., Dumy, P.: Tumor targeting with RGD peptide ligands-design of new molecular conjugates for imaging and therapy of cancers. Anticancer Agents Med. Chem. 7(5), 552–558 (2007)
18. Meyer, A., Auernheimer, J., Modlinger, A., et al.: Targeting RGD recognizing integrins: drug development, biomaterial research, tumor imaging and targeting. Curr. Pharm. Des. 12(22), 2723–2747 (2006)
19. Ruoslahti, E.: Specialization of tumour vasculature. Nat. Rev. Cancer 2(2), 83–90 (2002)
20. Sudimack, J., Lee, R.J.: Targeted drug delivery via the folate receptor. Adv. Drug Del. Rev. 41(2), 147–162 (2000)
21. Zhao, X., Li, H., Lee, R.J.: Targeted drug delivery via folate receptors. Expert Opin. Drug Deliv. 5(3), 309–319 (2008)
22. Lu, Y., Sega, E., Leamon, C.P., et al.: Folate receptor-targeted immunotherapy of cancer: mechanism and therapeutic potential. Adv. Drug Deliv. Rev. 56(8), 1161–1176 (2004)
23. Russell-Jones, G., McTavish, K., McEwan, J., et al.: Vitamin-mediated targeting as a potential mechanism to increase drug uptake by tumours. J. Inorg. Biochem. 98(10), 1625– 1633 (2004)
24. Shmeeda, H., Mak, L., Tzemach, D., et al.: Intracellular uptake and intracavitary targeting of folate-conjugated liposomes in a mouse lymphoma model with up-regulated folate receptors. Mol. Cancer Ther. 5(4), 818–824 (2006)
25. Wu, J., Liu, Q., Lee, R.J.: A folate receptor-targeted liposomal formulation for paclitaxel. Int. J. Pharm. 316(1–2), 148–153 (2006)
26. Wu, A.M., Senter, P.D.: Arming antibodies: prospects and challenges for immunoconjugates. Nat. Biotechnol. 23(9), 1137–1146 (2005)
27. Niculescu-Duvaz, I., Springer, C.J.: Antibody-directed enzyme prodrug therapy (ADEPT): a review. Adv. Drug Del. Rev. 26(2–3), 151–172 (1997)
28. Ferrari, M.: Cancer nanotechnology: opportunities and challenges. Nat. Rev. Cancer 5(3), 161–171 (2005)
29. Heister, E., Neves, V., Tîlmaciu, C., et al.: Triple functionalisation of single-walled carbon nanotubes with doxorubicin, a monoclonal antibody, and a fluorescent marker for targeted cancer therapy. Carbon 47(9), 2152–2160 (2009)
30. Iyer, A.K., Khaled, G., Fang, J., et al.: Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov. Today 11(17–18), 812–818 (2006)
31. Gottlieb, J.J., Washenik, K., Chachoua, A., et al.: Treatment of classic Kaposi’s sarcoma with liposomal encapsulated doxorubicin. Lancet 350(9088), 1363–1364 (1997)
32. Tannock, I.F., Rotin, D.: Acid pH in tumors and its potential for therapeutic exploitation. Cancer Res. 49(16), 4373–4384 (1989)
33. Ko, J., Park, K., Kim, Y.S., et al.: Tumoral acidic extracellular pH targeting of pH-responsive MPEG-poly (beta-amino ester) block copolymer micelles for cancer therapy. J Control. Release 123(2), 109–115 (2007)
34. Pantarotto, D., Briand, J.P., Prato, M., et al.: Translocation of bioactive peptides across cell membranes by carbon nanotubes. Chem. Commun. (1), 16–17 (2004)
35. Kam, N.W.S., Jessop, T.C., Wender, P.A., et al.: Nanotube molecular transporters: internalization of carbon nanotube-protein conjugates into mammalian cells. J. Am. Chem. Soc. 126(22), 6850–6851 (2004)
36. Pantarotto, D., Singh, R., McCarthy, D., et al.: Functionalized carbon nanotubes for plasmid DNA gene delivery. Angew. Chem. Int. Edn. 43(39), 5242–5246 (2004)
37. Gao, L.Z., Nie, L., Wang, T.H., et al.: Carbon nanotube delivery of the GFP gene into mammalian cells. ChemBioChem 7(2), 239–242 (2006)
38. Kam, N.W.S., Liu, Z.A., Dai, H.J.: Carbon nanotubes as intracellular transporters for proteins and DNA: an investigation of the uptake mechanism and pathway. Angew. Chem. Int. Edn. 45(4), 577–581 (2006)
39. Chen, J., Chen, S., Zhao, X., et al.: Functionalized single-walled carbon nanotubes as rationally designed vehicles for tumor-targeted drug delivery. J. Am. Chem. Soc. 130(49), 16778–16785 (2008)
40. Kam, N.W.S., Liu, Z., Dai, H.J.: Functionalization of carbon nanotubes via cleavable disulfide bonds for efficient intracellular delivery of siRNA and potent gene silencing. J. Am. Chem. Soc. 127(36), 12492–12493 (2005)
41. Prabaharan, M., Grailer, J.J., Pilla, S., et al.: Gold nanoparticles with a monolayer of doxorubicin-conjugated amphiphilic block copolymer for tumor-targeted drug delivery. Biomaterials 30(30), 6065–6075 (2009)
42. Yudasaka, M., Ajima, K., Suenaga, K., et al.: Nano-extraction and nano-condensation for C-60 incorporation into single-wall carbon nanotubes in liquid phases. Chem. Phys. Lett. 380(1–2), 42–46 (2003)
43. Leonhardt, A., Hampel, S., Muller, C., et al.: Synthesis, properties, and applications of ferromagnetic-filled carbon nanotubes. Chem. Vap. Deposition 12(6), 380–387 (2006)
44. Gao, H.J., Kong, Y., Cui, D.X., et al.: Spontaneous insertion of DNA oligonucleotides into carbon nanotubes. Nano Lett. 3(4), 471–473 (2003)
45. Kim, B.M., Qian, S., Bau, H.H.: Filling carbon nanotubes with particles. Nano Lett. 5(5), 873–878 (2005)
46. Hilder, T.A., Hill, J.M.: Carbon nanotubes as drug delivery nanocapsules. Curr. Appl. Phys. 8(3–4), 258–261 (2008)
47. Hilder, T.A., Hill, J.M.: Probability of encapsulation of paclitaxel and doxorubicin into carbon nanotubes. Micro Nano Lett. 3(2), 41–49 (2008)
48. Wu, W., Wieckowski, S., Pastorin, G., et al.: Targeted delivery of amphotericin B to cells by using functionalized carbon nanotubes. Angew. Chem. Int. Ed. 44(39), 6358–6362 (2005)
49. Ali-Boucetta, H., Al-Jamal, K.T., McCarthy, D., et al.: Multiwalled carbon nanotube-doxorubicin supramolecular complexes for cancer therapeutics. Chem. Commun. (4), 459–461 (2008)
50. Feazell, R.P., Nakayama-Ratchford, N., Dai, H., et al.: Soluble single-walled carbon nanotubes as longboat delivery systems for Platinum(IV) anticancer drug design. J. Am. Chem. Soc. 129(27), 8438–8439 (2007)
51. Liu, Z., Sun, X.M., Nakayama-Ratchford, N., et al.: Supramolecular chemistry on water-soluble carbon nanotubes for drug loading and delivery. ACS Nano 1(1), 50–56 (2007)
52. Dhar, S., Liu, Z., Thomale, J., et al.: Targeted single-wall carbon nanotube-mediated Pt(IV) prodrug delivery using folate as a homing device. J. Am. Chem. Soc. 130(34), 11467–11476 (2008)
53. Hampel, S., Kunze, D., Haase, D., et al.: Carbon nanotubes filled with a chemotherapeutic agent: a nanocarrier mediates inhibition of tumor cell growth. Nanomedicine 3(2), 175–182 (2008)
54. Ou, Z.M., Wu, B.Y., Xing, D., et al.: Functional single-walled carbon nanotubes based on an integrin alpha(v)beta(3) monoclonal antibody for highly efficient cancer cell targeting. Nanotechnology 20(10), 105102 (2009)
55. Zhang, X.K., Meng, L.J., Lu, Q.G., et al.: Targeted delivery and controlled release of doxorubicin to cancer cells using modified single wall carbon nanotubes. Biomaterials 30(30), 6041–6047 (2009)
56. McDevitt, M.R., Chattopadhyay, D., Kappel, B.J., et al.: Tumor targeting with antibody-functionalized, radiolabeled carbon nanotubes. J. Nucl. Med. 48(7), 1180–1189 (2007)
57. Scott, S.D.: Rituximab: a new therapeutic monoclonal antibody for non-Hodgkin’s lymphoma. Cancer Pract. 6(3), 195–197 (1998)
58. Liu, Z., Chen, K., Davis, C., et al.: Drug delivery with carbon nanotubes for in vivo cancer treatment. Cancer Res. 68(16), 6652–6660 (2008)
59. Villa, C.H., McDevitt, M.R., Escorcia, F.E., et al.: Synthesis and biodistribution of oligonucleotide-functionalized, tumor-targetable carbon nanotubes. Nano Lett. 8(12), 4221– 4228 (2008)
60. Bhirde, A.A., Patel, V., Gavard, J., et al.: Targeted killing of cancer cells in vivo and in vitro with EGF-directed carbon nanotube-based drug delivery. ACS Nano 3(2), 307–316 (2009)
61. Wu, W., Li, R.T., Bian, X.C., et al.: Covalently combining carbon nanotubes with anticancer agent: preparation and antitumor activity. ACS Nano 3(9):2740–2750 (2009)
62. Zeineldin, R., Al-Haik, M., Hudson, L.G.: Role of polyethylene glycol integrity in specific receptor targeting of carbon nanotubes to cancer cells. Nano Lett. 9(2), 751–757 (2009)